Disease-modifying treatment trials are increasingly advanced to the prodromal or preclinical
phase of Alzheimer's disease (AD), and inclusion criteria are based on biomarkers rather …

Background: Evidence suggests that the concordance between amyloid-PET and cerebrospinal
fluid (CSF) amyloid-ß (Aß) increases when the CSF Aß1–42/Aß1–40 ratio is used as …

Alzheimer’s disease CSF biomarkers 42 amino acid long amyloid-β peptide (Aβ 1–42 ),
total tau protein (T-tau), and tau protein phosphorylated at threonine 181 (P-tau 181 ) are …

During the past ten years, over 5,000 cerebrospinal fluid (CSF) samples were analyzed at
the Reference Center for Biological Markers of Dementia (BIODEM), UAntwerp, for core …

We aimed to evaluate the specificity of neurogranin (Ng) for Alzheimer's disease (AD) in a
dementia cohort. Cerebrospinal fluid (CSF) Ng was measured (ELISA) in two independent …

Increased brain uptake of 18 F-AV45 visualized by PET is a key biomarker for Alzheimer
disease (AD). The SUV ratio (SUVR) is widely used for quantification, but is subject to variability …

Background The Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarkers Aβ 1–42 , t-tau,
and p-tau 181 overlap with other diseases. New tau modifications or epitopes, such as …

Background: Despite decades of research on the optimization of the diagnosis of Alzheimer’s
disease (AD), its biomarkerbased diagnosis is being hampered by the lack of …

Although the core cerebrospinal fluid Alzheimer's disease (AD) biomarkers amyloid-β (Aβ 1–42
) and tau show a high diagnostic accuracy, there are still limitations due to overlap in the …

Over the last couple of decades, cerebrospinal fluid (CSF) biomarkers have been studied
thoroughly for their potential to closely reflect neuropathological processes in the brain. To date…